Who
Kevin Balthaser
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Aclaris Therapeutics.
In numbers
- Trades disclosed
- 94
- Buys
- 1
- Sells
- 2
- Bought
- $75K
- Sold
- $24K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Feb 2023
- Last trade
- 1 Mar 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Mar 2026filed 3 Mar 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,375 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,943677 at $2.87 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,375 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,375 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,375 | filing |
| 1 Mar 2026filed 3 Mar 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,943677 at $2.87 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —22,025 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code F | $22K6,449 at $3.47 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —22,025 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —22,025 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —22,025 | filing |
| 3 Feb 2026filed 5 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code F | $22K6,449 at $3.47 | filing |
| 2 Feb 2026filed 6 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —99,100 at $0.00 | filing |
| 2 Feb 2026filed 6 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —346,800 at $0.00 | filing |
| 2 Feb 2026filed 6 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —99,100 at $0.00 | filing |
| 2 Feb 2026filed 6 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —346,800 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —14,750 | filing |
| 1 Feb 2026filed 3 Feb 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code F | $17K4,984 at $3.51 | filing |
| 1 Feb 2026filed 3 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,750 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,750 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.